Market News

Codiak BioSciences (NASDAQ: CDAK) Drops Following Planned Public Offering

Shares of Codiak BioSciences (NASDAQ: CDAK) dropped in pre-market trading on Tuesday as the clinical-stage biopharmaceutical company announced the pricing of 13.3 million shares and accompanying warrants to purchase at a combined public offering price of $1.50 per share, together with the warrants, for gross proceeds of around $20 million.

The warrants have an exercise price of $1.875 per share which can be exercised immediately and will expire five years from the date of issuance.

The offering is expected to close on September 15, 2022.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More